UTMD logo

Utah Medical Products, Inc. Stock Price

NasdaqGS:UTMD Community·US$196.6m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

UTMD Share Price Performance

US$61.33
-5.19 (-7.80%)
US$61.33
-5.19 (-7.80%)
Price US$61.33

UTMD Community Narratives

There are no narratives available yet.

Recent UTMD News & Updates

Utah Medical Products (NASDAQ:UTMD) Has Affirmed Its Dividend Of $0.305

Aug 01
Utah Medical Products (NASDAQ:UTMD) Has Affirmed Its Dividend Of $0.305

Utah Medical Products: Deep Discount Is Drawing One Legendary Investor's Interest

Jul 03

Utah Medical Products: Quietly Profitable--A Deep Value Gem Hiding In The Open

Apr 16

Some May Be Optimistic About Utah Medical Products' (NASDAQ:UTMD) Earnings

Apr 07
Some May Be Optimistic About Utah Medical Products' (NASDAQ:UTMD) Earnings

Utah Medical Products, Inc. Key Details

US$38.8m

Revenue

US$16.6m

Cost of Revenue

US$22.3m

Gross Profit

US$9.7m

Other Expenses

US$12.6m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
3.92
Gross Margin
57.33%
Net Profit Margin
32.33%
Debt/Equity Ratio
0%

Utah Medical Products, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet established dividend payer.

0 Risks
2 Rewards

About UTMD

Founded
1978
Employees
161
CEO
Kevin Cornwell
WebsiteView website
www.utahmed.com

Utah Medical Products, Inc. provides medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company also provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. The company serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 5.1%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.7%, driven by a decline of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›